Reaction

Metastases To Pleura reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,028 reports · 49 co-occurring drugs

As of the last recalculation, Metastases To Pleura appears in 1,028 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is FULVESTRANT (PRR 121.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fulvestrant	166	121.1	121.8
Exemestane	86	88.6	89.0
Gefitinib	34	78.8	79.1
Ribociclib	105	74.9	75.2
Letrozole Tablets	133	64.1	64.3
Letrozole	158	61.2	61.3
Everolimus Tablets	43	54.1	54.3
Goserelin	34	53.0	53.1
Alpelisib	22	52.2	52.3
Ado-Trastuzumab Emtansine	19	46.5	46.6
Everolimus	102	44.9	45.0
Anastrozole Tablets	37	36.2	36.2
Capecitabine	135	34.2	34.3
Fam-Trastuzumab Deruxtecan-Nxki	15	30.6	30.6
Erlotinib	14	29.7	29.7
Anastrozole	51	29.5	29.6
Docetaxel Anhydrous	89	29.2	29.2
Docetaxel	89	29.2	29.2
Pemetrexed	30	29.1	29.2
Osimertinib	44	29.0	29.0
Abemaciclib	27	28.1	28.1
Olaparib	28	27.8	27.9
Paclitaxel (Aibumin-Bound)	99	26.9	26.9
Erlotinib Hydrochloride	15	24.6	24.6
Paclitaxel	105	23.8	23.8
Zoledronic Acid	44	23.1	23.2
Pemetrexed Disodium	37	20.4	20.4
Gemcitabine	35	18.6	18.6
Pertuzumab	24	18.3	18.3
Durvalumab	18	18.2	18.2
Trastuzumab	58	18.1	18.1
Gemcitabine Hydrochloride	38	15.0	15.0
Carboplatin	85	14.7	14.7
Bevacizumab	82	14.5	14.5
Pazopanib Hydrochloride	19	14.5	14.5
Sorafenib	14	13.8	13.8
Lapatinib	10	13.2	13.2
Fluorouracil Cream, 0.5%	47	13.0	13.0
Palbociclib	58	13.0	13.0
Fluorouracil	47	12.8	12.8
Trametinib	15	12.7	12.7
Dabrafenib	13	12.6	12.6
Atezolizumab	20	10.6	10.6
Regorafenib	6	10.5	10.5
Cisplatin	39	10.5	10.5
Nivolumab	41	8.9	8.9
Denosumab	74	7.9	7.9
Cabozantinib	15	6.4	6.4
Crizotinib	4	6.4	6.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.